Preoperative Systemic Immune-Inflammation Index (SII) for Predicting the Survival of Patients with Stage I-III Gastric Cancer with a Signet-Ring Cell (SRC) Component

Table 4

Analysis of prognostic factors in 512 patients with gastric cancer with an SRC component.

Variables	Survival analysis
	5-YSR (%)	value
Sex
Male	53.3	0.639
Female	51.7
Age (years)
<55	58.5	0.007
≥55	47.4
Tumor size (cm)
<4.75	72.8	<0.001
≥4.75	36.6
Chemotherapy
Yes	56.6	0.059
No	49.3
SRCC
mSRCC	53.6	0.432
pSRCC	47.1
T-stage
T1	97.6	<0.001
T2	82.8
T3	50.0
T4	34.4
N-stage
N0	83.1	<0.001
N1	55.8
N2	47.0
N3a	30.4
N3b	10.3
TNM
I+II	80.9	<0.001
III	31.5
Tumor location
L	59.5	<0.001
M	49.3
U	37.1
LM	37.7
MU	28.6
LMU	21.4
Leukocyte
<6.17	55.1	0.229
≥6.17	49.5
Neutrophil
<3.27	56.9	0.046
≥3.27	48.4
Hemoglobin
<121.2	40.0	<0.001
≥121.2	57.5
Fibrinogen
<3.06	62.3	<0.001
≥3.06	42.2
Prealbumin
<234.5	39.7	<0.001
≥234.5	64.9
Albumin
<42.5	46.2	<0.001
≥42.5	61.4
Globulin
<29.9	54.1	0.170
≥29.9	46.0
NLR
<2.2	59.1	0.006
≥2.2	40.1
PNI
<48.73	38.1	<0.001
≥48.73	60.4
SII
<527	60.0	<0.001
≥527	38.4
Total gastrectomy
Yes	22.1	<0.001
No	61.4

SII: systemic immune-inflammation index; SRCC: signet-ring cell carcinoma; pSRCC: pure signet-ring cell cancer; mSRCC: mixed signet-ring cell cancer; LM: lower and middle; MU: middle and upper; LMU: lower, middle, and upper; PNI: prognostic nutritional index; NLR: lymphocyte to neutrophil ratio.